Corporate-backed medical imaging technology producer Lunit is preparing to float in South Korea while cancer drug developer Pheast secured $76m from investors including Alexandria Venture Investments.

The Sinopharm-backed laboratory animal model developer floated on Shanghai Stock Exchange’s Star Market two years after its last equity funding.

The audio streaming service is set to list with help from a PIPE deal featuring Orange, Access Industries, Warner Music, UMG and Media Participations.

Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.

The Takeda spinoff is developing a vaccine for acute gastroenteritis caused by norovirus infection, and raised about $140m in August 2021.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.

DigitalBridge Ventures led wireless adoption software developer Celona's $60m series C round while Papaya is paying up to $200m for Rakuten-backed payment platform developer Azimo.

The multicorporate-backed diversified mobile app operator has listed on IDX having priced its shares at near the top of their range.

The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.